\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationBrussels
DG HOME has prepared a CERIS workshop, discussing security research contributions to preventing and countering corruption. The Community of European Research and Innovation for Security (CERIS) consists of practitioners, policymakers, civil society representatives and researchers relevant to the field of security research.
During this workshop, EU-funded projects will be discussed (lessons learned, latest insights, etc.). It will be held physically in Brussels, Bouche à Oreille on 22 November 2023.
Registration and agenda details can be found here. Registration is free, but mandatory.
Draft agenda:
09:00 - Registration & coffee
09:30 - Welcome address & keynote speech
10:00 - Panel 1: Tools and approaches to prevent corruption
11:30 - Coffee break
12:00 - Panel 2: Detection and investigation of corruption crime
13:30 - Lunch
14:30 - Panel 3: New and emerging challenges related to corruption
16:00 - Wrap-up & closing
16:15 - Coffee
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space AI Continent Semiconductors
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
